Interact with experts and peers.

Recent Posts

10 of 58 Shown
  • A Quandary Over Switching: When Patients Resist My Recommendation to Switch

    David A. Wohl MD - 10/15/2014
    I usually recommend patients who are still receiving lopinavir/ritonavir-based regimens to switch. But how strongly should I urge them to switch when they are reluctant?
  • Choosing a Single-Tablet Regimen for HIV Patients: What Do the Latest IAS-USA Guidelines Have to Say?

    Renslow Sherer MD - 10/7/2014
    How I apply recent guidelines in daily practice to offer eligible patients the benefits of single-tablet regimens.
  • To Switch or Not to Switch: Management of First-line Boosted PI Virologic Failure

    W. David Hardy MD - 10/7/2014
    After a first-line boosted PI regimen fails virologically, when is it OK to stay the course vs making a regimen switch?
  • Deintensification Strategies Using Boosted PIs: Are They Ready for Prime Time?

    Paul E. Sax MD - 10/7/2014
    Recent studies have highlighted the potential efficacy of 2-drug boosted PI regimens. Are you considering integrating these strategies into your practice?
  • Should We Test for Integrase Inhibitor Resistance in Our Treatment-Naive Patients?

    Joseph J. Eron, Jr. MD - 9/22/2014 2 comments / Last Comment: 9/25/2014
    And if we do, how should we interpret and act upon the results? Here’s what I did in one of my patient cases.
  • Sizing Up the Newest Integrase Inhibitor–Based Single-Tablet Regimen

    William G. Powderly MD - 9/22/2014 1 comment / Last Comment: 9/25/2014
    When it comes to ART, choice is good. And the recent FDA approval of the dolutegravir/abacavir/lamivudine single-tablet regimen contributes a very significant addition to our choices.
  • Should Integrase Inhibitor Regimens Be Your First Choice When Starting HIV Therapy?

    Eric S. Daar MD - 8/25/2014
    Recently, one of my patients asked me why anyone would not choose to start therapy with one of the INSTI-based regimens. Here’s how I responded.
  • What 5257 Tells Us About the Selection of Integrase Inhibitor Regimens For HIV Therapy

    Joseph J. Eron, Jr. MD - 8/20/2014 1 comment / Last Comment: 9/5/2014
    Recent data may support the argument for selecting integrase inhibitors as first-line therapy for the majority of our patients. Get an idea of the key considerations I and my colleagues will discuss at an upcoming symposium addressing this question.
  • Using Boosted Protease Inhibitors in the Aftermath of ACTG 5257

    Kathleen E. Squires MD - 7/14/2014 2 comments / Last Comment: 7/31/2014
    The ACTG 5257 study was very informative for clinicians because its study design looked at the “real world’ endpoints of virologic failure and tolerability failure, defined as the ability for individuals to stay on regimens they were originally assigned to.
  • Challenges of Treating Drug-Resistant TB in Developing Countries

    Francesca Conradie MBBCh - 7/9/2014 3 comments / Last Comment: 8/14/2014
    As a clinician treating MDR-TB in South Africa, I am very familiar with the challenges, but new rapid diagnostic tests to detect drug resistance and drugs such as bedaquiline are making a clinical difference.
10 of 58 Shown
Show 10 More